<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766415</url>
  </required_header>
  <id_info>
    <org_study_id>D9831C00002</org_study_id>
    <nct_id>NCT00766415</nct_id>
  </id_info>
  <brief_title>14729-D9831C00002- 1 Month Biopsy Study</brief_title>
  <acronym>Biopsy</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study histological changes, cellularity, clinical efficacy
      and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aggregated Pathology Score</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Composite endpoint subscores: histological grade, immunohistochemistry grade, leucocyte counts. Each subscore measured on scale 1 (normal) to 5 (worst outcome). Composite score summed across the subscores, ranging from 3 (normal) to 15 (worst outcome). Change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Eosinophil Count (%)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Eosinophil count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Neutrophil Count (%)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Neutrophil count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Macrophages Count (%)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Macrophages count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Lymphocytes Count (%)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Lymphocytes count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Epithelial Cells Count (%)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Epithelial cells count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL): Total Cells Count</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Bronchoalveolar Lavage (BAL): Total cells count from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Eosinophil Count (%)</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Eosinophil count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Neutrophils Count (%)</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Neutrophils count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Macrophages Count (%)</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Macrophages count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Lymphocytes Count (%)</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Lymphocytes count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Epithelial Cells Count (%)</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Epithelial cells count (% of total) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced Sputum: Total Cells Count</measure>
    <time_frame>Before and after 3 week treatment</time_frame>
    <description>Change in Induced sputum Total cells count from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chronic Obstructive Pulmonary Disease (COPD) The Clinical COPD Questionnaire (CCQ)</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Change in total CCQ score from baseline to last measurement on treatment. scored on a scale of 0 - 6. 0 =(low symptoms)-6 =(high symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Morning</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in Peak Expiratory Flow (PEF) morning from baseline to the average of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Evening</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in Peak Expiratory Flow (PEF) evening from baseline to the average of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) Symptom Night-time Awakenings Score</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in COPD symptom night-time awakening score from baseline to the average of the treatment period. 0=(no symptom)-4=(no sleep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) Symptom Breathing Score</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in COPD symptom breathing score from baseline to the average of the treatment period. 0= (none) - 4 =(severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) Symptom Cough Score</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in COPD symptom cough score from baseline to the average of the treatment period. 0= (none) - 4= (almost constant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) Symptom Sputum Score</measure>
    <time_frame>Before and after 1 month treatment</time_frame>
    <description>Mean change in COPD symptom sputum score from baseline to the average of the treatment period. 0= (none) - 4= (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with an Adverse Event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>AZD1981</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>Oral tablet, twice daily, 4 weeks treatment</description>
    <arm_group_label>AZD1981</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 40 years or above

          -  FEV1 between 40 and 80% of predicted normal value post-bronchodilator

          -  Clinical diagnosis of COPD

        Exclusion Criteria:

          -  Other clinically relevant disease or disorders

          -  Exacerbation of COPD within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Krug</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fraunhofer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frieburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GROßHANSDORF</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=216&amp;filename=CSR-D9831C00002.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=216&amp;filename=CSR-D9831C00002.pdf</url>
    <description>CSR-D9831C00002.pdf</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Moderate to severe COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>84 patients enrolled, 52 were randomised, 1 patient discontinued before treatment start and 51 patients completed the study. First patient entered the study on 17 November 2008 and the last patient finished the study on 10 June 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1981</title>
          <description>AZD1981 1000 mg, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient randomised to the placebo group voluntarily discontinued from the study after randomisation before receiving any investigational product. This patient is excluded from the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>AZD1981</title>
          <description>AZD1981 1000 mg, twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>1 participant discontinued immediately following randomization, did not start treatment and have not been included in any of the efficacy or safety calculations.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="50" upper_limit="75"/>
                    <measurement group_id="B2" value="61.1" lower_limit="41" upper_limit="80"/>
                    <measurement group_id="B3" value="61" lower_limit="41" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>1 participant discontinued immediately following randomization, did not start treatment and have not been included in any of the efficacy or safety calculations.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aggregated Pathology Score</title>
        <description>Composite endpoint subscores: histological grade, immunohistochemistry grade, leucocyte counts. Each subscore measured on scale 1 (normal) to 5 (worst outcome). Composite score summed across the subscores, ranging from 3 (normal) to 15 (worst outcome). Change from baseline.</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Aggregated Pathology Score</title>
          <description>Composite endpoint subscores: histological grade, immunohistochemistry grade, leucocyte counts. Each subscore measured on scale 1 (normal) to 5 (worst outcome). Composite score summed across the subscores, ranging from 3 (normal) to 15 (worst outcome). Change from baseline.</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="7.43" lower_limit="7.43" upper_limit="8.34"/>
                    <measurement group_id="O2" value="8.15" spread="7.68" lower_limit="7.68" upper_limit="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Eosinophil Count (%)</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Eosinophil count (% of total) from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Eosinophil Count (%)</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Eosinophil count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="-2.22" lower_limit="-2.22" upper_limit="-0.94"/>
                    <measurement group_id="O2" value="-1.45" spread="-2.13" lower_limit="-2.13" upper_limit="-0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Neutrophil Count (%)</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Neutrophil count (% of total) from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Neutrophil Count (%)</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Neutrophil count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="-12.94" lower_limit="-12.94" upper_limit="8.46"/>
                    <measurement group_id="O2" value="-5.67" spread="-16.75" lower_limit="-16.75" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Macrophages Count (%)</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Macrophages count (% of total) from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Macrophages Count (%)</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Macrophages count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.84" spread="-1.51" lower_limit="-1.51" upper_limit="21.20"/>
                    <measurement group_id="O2" value="10.68" spread="-1.24" lower_limit="-1.24" upper_limit="22.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Lymphocytes Count (%)</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Lymphocytes count (% of total) from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Lymphocytes Count (%)</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Lymphocytes count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="-3.04" lower_limit="-3.04" upper_limit="0.11"/>
                    <measurement group_id="O2" value="-0.37" spread="-2.02" lower_limit="-2.02" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Epithelial Cells Count (%)</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Epithelial cells count (% of total) from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Epithelial Cells Count (%)</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Epithelial cells count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.18" spread="-11.80" lower_limit="-11.80" upper_limit="3.45"/>
                    <measurement group_id="O2" value="-2.98" spread="-10.98" lower_limit="-10.98" upper_limit="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL): Total Cells Count</title>
        <description>Change in Bronchoalveolar Lavage (BAL): Total cells count from baseline</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL): Total Cells Count</title>
          <description>Change in Bronchoalveolar Lavage (BAL): Total cells count from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>10^6/g</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="-0.10" lower_limit="-0.10" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.04" spread="-0.10" lower_limit="-0.10" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Eosinophil Count (%)</title>
        <description>Change in Induced sputum Eosinophil count (% of total) from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Eosinophil Count (%)</title>
          <description>Change in Induced sputum Eosinophil count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="-3.30" lower_limit="-3.30" upper_limit="-0.98"/>
                    <measurement group_id="O2" value="-0.81" spread="-1.92" lower_limit="-1.92" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Neutrophils Count (%)</title>
        <description>Change in Induced sputum Neutrophils count (% of total) from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Neutrophils Count (%)</title>
          <description>Change in Induced sputum Neutrophils count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="-12.79" lower_limit="-12.79" upper_limit="14.19"/>
                    <measurement group_id="O2" value="3.73" spread="-8.84" lower_limit="-8.84" upper_limit="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Macrophages Count (%)</title>
        <description>Change in Induced sputum Macrophages count (% of total) from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Macrophages Count (%)</title>
          <description>Change in Induced sputum Macrophages count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="-11.95" lower_limit="-11.95" upper_limit="14.57"/>
                    <measurement group_id="O2" value="-7.79" spread="-20.27" lower_limit="-20.27" upper_limit="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Lymphocytes Count (%)</title>
        <description>Change in Induced sputum Lymphocytes count (% of total) from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Lymphocytes Count (%)</title>
          <description>Change in Induced sputum Lymphocytes count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="-0.21" lower_limit="-0.21" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.02" spread="-0.17" lower_limit="-0.17" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Epithelial Cells Count (%)</title>
        <description>Change in Induced sputum Epithelial cells count (% of total) from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Epithelial Cells Count (%)</title>
          <description>Change in Induced sputum Epithelial cells count (% of total) from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="-6.01" lower_limit="-6.01" upper_limit="5.01"/>
                    <measurement group_id="O2" value="4.11" spread="-1.04" lower_limit="-1.04" upper_limit="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induced Sputum: Total Cells Count</title>
        <description>Change in Induced sputum Total cells count from baseline</description>
        <time_frame>Before and after 3 week treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Sputum: Total Cells Count</title>
          <description>Change in Induced sputum Total cells count from baseline</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>10^6/g</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="-3.21" lower_limit="-3.21" upper_limit="1.08"/>
                    <measurement group_id="O2" value="-1.69" spread="-4.07" lower_limit="-4.07" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of treatment</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of treatment</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="-15.94" lower_limit="-15.94" upper_limit="6.40"/>
                    <measurement group_id="O2" value="6.16" spread="-5.66" lower_limit="-5.66" upper_limit="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chronic Obstructive Pulmonary Disease (COPD) The Clinical COPD Questionnaire (CCQ)</title>
        <description>Change in total CCQ score from baseline to last measurement on treatment. scored on a scale of 0 - 6. 0 =(low symptoms)-6 =(high symptoms)</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chronic Obstructive Pulmonary Disease (COPD) The Clinical COPD Questionnaire (CCQ)</title>
          <description>Change in total CCQ score from baseline to last measurement on treatment. scored on a scale of 0 - 6. 0 =(low symptoms)-6 =(high symptoms)</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="-0.69" lower_limit="-0.69" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.34" spread="-0.68" lower_limit="-0.68" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Morning</title>
        <description>Mean change in Peak Expiratory Flow (PEF) morning from baseline to the average of the treatment period</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Morning</title>
          <description>Mean change in Peak Expiratory Flow (PEF) morning from baseline to the average of the treatment period</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="-9.55" lower_limit="-9.55" upper_limit="14.69"/>
                    <measurement group_id="O2" value="-4.14" spread="-16.96" lower_limit="-16.96" upper_limit="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Evening</title>
        <description>Mean change in Peak Expiratory Flow (PEF) evening from baseline to the average of the treatment period</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Evening</title>
          <description>Mean change in Peak Expiratory Flow (PEF) evening from baseline to the average of the treatment period</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="-13.03" lower_limit="-13.03" upper_limit="15.65"/>
                    <measurement group_id="O2" value="1.46" spread="-14.27" lower_limit="-14.27" upper_limit="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Night-time Awakenings Score</title>
        <description>Mean change in COPD symptom night-time awakening score from baseline to the average of the treatment period. 0=(no symptom)-4=(no sleep)</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Night-time Awakenings Score</title>
          <description>Mean change in COPD symptom night-time awakening score from baseline to the average of the treatment period. 0=(no symptom)-4=(no sleep)</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="-0.47" lower_limit="-0.47" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.24" spread="-0.49" lower_limit="-0.49" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Breathing Score</title>
        <description>Mean change in COPD symptom breathing score from baseline to the average of the treatment period. 0= (none) - 4 =(severe).</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Breathing Score</title>
          <description>Mean change in COPD symptom breathing score from baseline to the average of the treatment period. 0= (none) - 4 =(severe).</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="-0.47" lower_limit="-0.47" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="-0.21" spread="-0.45" lower_limit="-0.45" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Cough Score</title>
        <description>Mean change in COPD symptom cough score from baseline to the average of the treatment period. 0= (none) - 4= (almost constant)</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Cough Score</title>
          <description>Mean change in COPD symptom cough score from baseline to the average of the treatment period. 0= (none) - 4= (almost constant)</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="-0.63" lower_limit="-0.63" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="-0.35" spread="-0.61" lower_limit="-0.61" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Sputum Score</title>
        <description>Mean change in COPD symptom sputum score from baseline to the average of the treatment period. 0= (none) - 4= (severe).</description>
        <time_frame>Before and after 1 month treatment</time_frame>
        <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Symptom Sputum Score</title>
          <description>Mean change in COPD symptom sputum score from baseline to the average of the treatment period. 0= (none) - 4= (severe).</description>
          <population>Efficacy analyses were performed on the full-analysis set, comprised of 51 patients: 25 in the AZD1981 group and 26 in the placebo group. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="-0.52" lower_limit="-0.52" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-0.38" spread="-0.60" lower_limit="-0.60" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event (AE)</title>
        <description>Number of participants with an Adverse Event</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 1000 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE)</title>
          <description>Number of participants with an Adverse Event</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>1 participant discontinued immediately following randomization, did not start treatment and have not been included in any of the efficacy or safety calculations.</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD1981</title>
          <description>AZD1981 1000 mg, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia After Bronchoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Holt</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

